Evidence map›Paper›PMID 31467037›Full record

ArticleThe Journal of experimental medicine2019

An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.

Hunter S Futch, Karen N McFarland, Brenda D Moore, M Zino Kuhn, Benoit I Giasson, Thomas B Ladd, Karen A Scott, Melanie R Shapiro, Rachel L Nosacka, Marshall S Goodwin and 12 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Hunter S FutchMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0002-5260-5736
Karen N McFarlandMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Brenda D MooreMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
M Zino KuhnMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Benoit I GiassonMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Thomas B LaddMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Karen A ScottMcKnight Brain Institute, Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL.ORCID 0000-0002-4133-423X
Melanie R ShapiroDiabetes Institute, Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0003-2090-0877
Rachel L NosackaDepartment of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL.
Marshall S GoodwinMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Yong RanMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0002-9748-4392
Pedro E CruzMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Daniel H RyuMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Cara L CroftMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0001-7969-5084
Yona LevitesMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Christopher JanusMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.
Paramita ChakrabartyMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0002-6226-3776
Andrew R JudgeDepartment of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL.
Todd M BruskoDiabetes Institute, Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL.ORCID 0000-0003-2878-9296
Annette D de KloetMcKnight Brain Institute, Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL.
Eric G KrauseMcKnight Brain Institute, Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, FL.
Todd E GoldeMcKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience and Neurology, College of Medicine, University of Florida, Gainesville, FL tgolde@ufl.edu.ORCID 0000-0003-1867-7071
University of Florida · US

Funding

Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, PETERS, METTE · 2013 to 2022
$24.6M
University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI GOLDE, TODD E · 2015 to 2019
$7.3M
Immune-Mediated Mechanisms Underlying CNS Abeta ClearanceR01AG018454 · NIA · UNIVERSITY OF FLORIDA · PI GOLDE, TODD E · 2000 to 2018
$5.3M
High-resolution Structural and Functional Brain Imaging of the Medial Temporal LoR01AG034613 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI STARK, CRAIG E · 2009 to 2018
$4.6M
Immunotherapy targeting the HPA axis in Alzheimer’s diseaseRF1AG064942 · NIA · UNIVERSITY OF FLORIDA · PI BIZON, JENNIFER LYNN, GOLDE, TODD E · 2019 to 2019
$4.0M
Targeting brain angiotensin signaling to discern and alleviate stress-related disease.R01HL139868 · NHLBI · UNIVERSITY OF FLORIDA · PI KRAUSE, ERIC GERALD · 2018 to 2019
$763k
Immunotherapeutic Targeting of Corticotropin-Releasing Hormone in Alzheimer's DiseaseF30NS105408 · NINDS · UNIVERSITY OF FLORIDA · PI FUTCH, HUNTER · 2017 to 2020
$137k
NHLBI NIH HHS R01 HL139868NIA NIH HHS P50 AG047266NIA NIH HHS R01 AG018454NIA NIH HHS R01 AG034613NIA NIH HHS RF1 AG064942NIA NIH HHS U01 AG046139NINDS NIH HHS F30 NS105408
6 · The paper itself

Abstract

Hypothalamic-pituitary-adrenal (HPA) axis dysfunction contributes to numerous human diseases and disorders. We developed a high-affinity monoclonal antibody, CTRND05, targeting corticotropin-releasing factor (CRF). In mice, CTRND05 blocks stress-induced corticosterone increases, counteracts effects of chronic variable stress, and induces other phenotypes consistent with suppression of the HPA axis. CTRND05 induces skeletal muscle hypertrophy and increases lean body mass, effects not previously reported with small-molecule HPA-targeting pharmacologic agents. Multiorgan transcriptomics demonstrates broad HPA axis target engagement through altering levels of known HPA-responsive transcripts such as Fkbp5 and Myostatin and reveals novel HPA-responsive pathways such as the Apelin-Apelin receptor system. These studies demonstrate the therapeutic potential of CTRND05 as a suppressor of the HPA axis and serve as an exemplar of a potentially broader approach to target neuropeptides with immunotherapies, as both pharmacologic tools and novel therapeutics.

Indexed as

AnimalsAntibodies, MonoclonalCell Line, TumorCorticosteroneCorticotropin-Releasing HormoneGene Expression ProfilingHumansHypothalamo-Hypophyseal SystemMice, Inbred BALB CMice, Inbred C57BLPhenotypePituitary-Adrenal SystemSignal TransductionStress, PhysiologicalAntibodies, MonoclonalCorticosteroneCorticotropin-Releasing Hormone

Identifiers

PMID31467037
PMCPMC6829597
OpenAlexW2971206297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.